Biocon Limited (NSE:BIOCON)
India
· Delayed Price · Currency is INR | Market Cap | 408.95B |
| Revenue (ttm) | 147.62B |
| Net Income (ttm) | 8.04B |
| Shares Out | 1.20B |
| EPS (ttm) | 6.71 |
| PE Ratio | 50.92 |
| Forward PE | 56.63 |
| Dividend | 0.50 (0.14%) |
| Ex-Dividend Date | Jul 5, 2024 |
| Volume | 2,338,864 |
| Average Volume | 2,435,124 |
| Open | 344.95 |
| Previous Close | 345.55 |
| Day's Range | 339.35 - 349.30 |
| 52-Week Range | 259.85 - 404.70 |
| Beta | 0.43 |
| RSI | 54.60 |
| Earnings Date | Apr 25, 2025 |
About Biocon
Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psor... [Read more]
Financial Performance
In 2023, Biocon's revenue was 147.56 billion, an increase of 32.05% compared to the previous year's 111.74 billion. Earnings were 10.23 billion, an increase of 120.99%.
Financial StatementsNews
Kiran Mazumdar Shaw Compares Bengaluru To Ecuador's Well-Designed Streets: "Hang Your Head In Shame"
Biocon chief Kiran Mazumdar Shaw on Thursday criticised Bengaluru's infrastructure and compared the city's streets to those in Ecuador.
Biocon stock in focus today: Biocon Pharma gets US FDA nod for norepinephrine injection
Biocon Limited announced on March 24, 2025, that its wholly owned subsidiary, Biocon Pharma Limited, has received approval from the U.S. Food and Drug Administration (US FDA) for its Abbreviated New D...
Stocks to watch today, March 10: Sun Pharma, ONGC, JSW Steel, Biocon, Omaxe and more
The Indian stock market has been experiencing significant movement, with the BSE Sensex rising by 1,134.48 points (1.55%) and the NSE Nifty gaining 427.8 points (1.93%) last week. However, today, Gift...
Stocks to watch today: TCS, IndiGo, BEL, Biocon, JSW Energy in Focus; Bajaj Finserv, Ola Electric, Go Fashion Decline on March 7, 2025
Indian stock markets will track key corporate developments today as multiple companies announced expansion plans, order wins, investments, and management changes. Stocks in Focus (Positive): TCS: Expa...
Stocks to Watch today: Kalpataru Projects, Bharat Electronics, Biocon, RVNL, Brigade, IndiGo, Power Grid in focus on March 7, 2025
Indian markets will track key corporate developments today, with several stocks in focus due to order wins, expansion plans, fundraising activities, and leadership changes. Stocks in News (Positive): ...
Stocks to watch today: Power Grid, ONGC, Adani Wilmar, Biocon, Apollo Hospitals, JSW Energy among stocks in focus on March 5, 2025
Indian stock markets are set for a volatile session today, with several major stocks in focus due to key developments across various sectors. Power Grid has been declared the successful bidder for thr...
Biocon Pharma secures US FDA approvals for Lenalidomide, Dasatinib, and Rivaroxaban tablets
Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received final approvals from the U.S. Food and Drug Administration (U.S. FDA) for multiple Abbreviated New Drug Applications (A...
Pharma Stocks: Glenmark down 2.43%, Divi’s Lab slips 2.10%, Biocon drops 2.57%, Glaxo plunges 3.44%, Nifty down 1.22%
The pharmaceutical sector experienced a broad-based decline, contributing to the overall market weakness as Nifty fell by 1.22% (-275.80 points) to 22,269.25. Glenmark dropped by 2.43%, closing at ₹1,...
Biocon launches Liraglutide for diabetes and obesity in the UK
Biocon Limited, a global biopharmaceutical leader, has announced the launch of its GLP-1 peptide, Liraglutide, in the United Kingdom (U.K.) for diabetes and chronic weight management. The drug will be...
Biocon shares surge 2.2% after its subsidiary launches YESINTEK™ in the US
Biocon Ltd. shares rose over 2% following the U.S. launch of YESINTEK™ (ustekinumab-kfce) by its subsidiary, Biocon Biologics Ltd. (BBL). As one of the first biosimilars to Stelara® (ustekinumab), YES...
Top stocks to watch today on February 25: Biocon, NTPC, Adani Green, Texmaco Rail and more
The Indian stock market is expected to open on a cautious note on Tuesday, influenced by multiple global and domestic factors. Market sentiment remains uncertain due to former U.S. President Donald Tr...
Biocon Biologics launches YESINTEK™ in the United States
Biocon Biologics Ltd. (BBL), a leading global biosimilars company and a subsidiary of Biocon Ltd., has announced the availability of YESINTEK™ (ustekinumab-kfce) in the United States. As one of the fi...
Biocon shares decline 6.67% this week; European Commission grants approval for YESINTEK
Biocon shares fell 6.67% this week, closing at ₹322.50 on February 21, 2025. The stock experienced a cumulative decline of ₹23.05 over the week, impacted by overall market volatility and sectoral corr...
Top Midcap Stock Losers This Week: CRISIL down 9.24%, Bharat Dynamics falls 8.43%, Biocon down 7.69% and more
The Nifty Midcap segment faced significant pressure this week, with several stocks witnessing steep losses. CRISIL emerged as the biggest loser, dropping 9.24% to close at ₹4,650.10. Bharat Dynamics f...
Top F&O Losers This Week: Mahindra and Mahindra falls 9.29%, Biocon drops 7.69%, Oracle Fin Serv down 6.23%
The Indian stock market saw a volatile week, with broader indices struggling under selling pressure. Among the top F&O losers, Mahindra & Mahindra (M&M) led the decline, dropping 9.29% to close at ₹2,...
India can overtake China in drug discovery: Biocon chief
Pune: India could adopt China's successful "fast follower" strategy in pharmaceutical innovation, Biocon chairperson Kiran Mazumdar-Shaw on Thursday s.
Biocon Biologics secures European Commission approval for its Ustekinumab Biosimilar
Biocon Biologics Ltd (BBL), a global leader in biosimilars and a subsidiary of Biocon Ltd, has received European Commission approval for YESINTEK®, a biosimilar of Ustekinumab. This milestone expands ...
Pharma stocks rally: Aurobindo Pharma up 4.05%, Lupin jumps 3.81%, Biocon gains 2.80% at market open
Pharmaceutical stocks opened on a strong note on Tuesday, with several leading companies witnessing sharp gains. Aurobindo Pharma surged 4.05% to ₹1,190.95, leading the sectoral rally and attracting s...
Biocon's growth formula: Generics & biosimilars
Biocon is set for major growth in the next 2-3 years, propelled by new generics and biosimilars. The Viatris acquisition strengthens its position in the U.S. market, with significant market share in s...
Biocon 'welcomes' India's duty exemptions on cancer, chronic disease drugs
Peter Bains, Group CEO of Biocon, talks about India's budget, and the impact of its plans to cut or remove duties on life-saving medicinal drugs. He also talks about the biopharma company's product pi...
Biocon shares in focus: HSBC sees 19% upside, Jefferies cautious post Q3 miss
Biocon shares are in the spotlight following a mixed Q3FY25 performance, with HSBC maintaining a bullish stance and Jefferies adopting a more cautious outlook. The stock is currently trading at ₹361.6...
Biocon raises stake in Biocon Biologics to 90.2% with Rs 5,550 crore acquisition
Biocon Limited has successfully completed the acquisition of 1.97 crore equity shares of its material subsidiary, Biocon Biologics Limited (BBL), from an existing investor for ₹5,550 crore in cash. Fo...
Biocon shares up nearly 3% as Q3 results highlight EBITDA growth of 16% and revenue rise of 7%
Biocon Limited’s shares surged nearly 3% to ₹366.75 on January 31 following the announcement of its Q3 FY25 financial results. The company reported all-round growth across its business segments, with ...
Top Q3 FY25 Results Today on January 30, 2025: Adani Enterprises, Adani Ports, Bajaj Finserv, BEL, Biocon, Dabur, Prestige Estates
A host of prominent companies, including Adani Enterprises, Adani Ports, Astral, Bajaj Finserv, Bank of Baroda, BEL, Biocon, Coromandel International, Dabur, Max Healthcare, Navin Fluorine, and Presti...
Syngene International shares fall nearly 6% on weak FY25 guidance and demand recovery delay
Shares of Syngene International Ltd, a subsidiary of Biocon, fell 5.91% to ₹796.90 on Friday, January 24, 2025, following a disappointing FY25 guidance update and concerns over delayed demand recovery...